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Objective: To evaluate the occurrence, clinical presentations and diagnostic methods for
tuberculosis  in a cohort of HIV-infected infants, children and adolescents from Latin Amer-
ica.
Methods:  A retrospective analysis of children with tuberculosis and HIV was performed
within  a prospective observational cohort study conducted at multiple clinical sites in Latin
America.
Results:  Of 1114 HIV-infected infants, children, and adolescents followed from 2002 to 2011,
69  that could be classiﬁed as having conﬁrmed or presumed tuberculosis were  included in
this case series; 52.2% (95% CI: 39.8–64.4%) had laboratory-conﬁrmed tuberculosis, 15.9%
(95%  CI: 8.2–26.7%) had clinically conﬁrmed disease and 31.9% (95% CI: 21.2–44.2%) had pre-
sumed  tuberculosis. Sixty-six were perinatally HIV-infected. Thirty-two (61.5%) children had
a history of contact with an adult tuberculosis case; however information on exposure to
active  tuberculosis was missing for 17 participants. At the time of tuberculosis diagnosis, 39
were receiving antiretroviral therapy. Sixteen of these cases may have represented immune
reconstitution  inﬂammatory syndrome.
Conclusions: Our study emphasizes the need for adequate contact tracing of adult tuber-
culosis  cases and screening for HIV or tuberculosis in Latin American children diagnosedwith  either condition. Preventive strategies in tuberculosis-exposed, HIV-infected children
should  be optimized.
© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND∗ Corresponding author.
E-mail  address: Margotkrauss@westat.com (M.R. Krauss).
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Introduction
HIV/AIDS is responsible for exacerbating the tuberculosis (TB)
epidemics  in both adults and children in many  low and middle
income  countries.1 Unfortunately, diagnosing TB in children
is  a challenging task because symptoms are non-speciﬁc and
sputum  specimens are usually not accessible, making bacte-
riologic  conﬁrmation difﬁcult.
Diagnosis in children often requires reliance on clinical,
epidemiological, and radiographic criteria.1 The diagno-
sis  of TB is further complicated in HIV-infected children2
presenting with advanced immune-suppression when Pneu-
mocystis  jiroveci, disseminated bacterial, fungal and viral
infections, or other mycobacterial agents mimic  or coexist
with  TB disease, and treatment is started empirically for
more  than one etiological agent in severely ill patients.3
Interpretation of tuberculin skin tests is difﬁcult, with false
negative  results occurring in HIV-infected children who are
immunocompromised and false positive results occurring in
Latin-American regions with moderate to high endemicity like
Brazil, where BCG is routinely given at birth.4,5
Many  investigators have reported on pediatric HIV-TB
co-infection in Africa,6–9 but few such studies have been con-
ducted  in Latin America.10–12 The largest Latin American study
reported  29 cases of TB in a cohort of 360 HIV-infected chil-
dren  using a retrospective, chart abstraction of hospitalization
records between 1989 and 1999.10 Most cases in this study had
pulmonary  disease; bacteriological conﬁrmation was  obtained
in  half of the cases, and no data on antiretroviral therapy (ART)
were  reported.
The  main purpose of our study was  to describe cases of TB
occurring  in HIV-infected children and youth who were par-
ticipating  in a large, multicenter observational cohort study
conducted  in Latin American countries. Our aims included
describing HIV-TB co-infection, methods used to diagnose TB
cases,  clinical presentation, the timing of the TB diagnosis in
relation to timing of initiating treatment for HIV, therapeu-
tic  response to TB treatment, and the association between TB
clinical  presentation and patient immunological status (when
appropriate  data were  available).
Methods
The Eunice Kennedy Shriver National Institute of Child Health
and  Human Development (NICHD) International Site Devel-
opment  Initiative (NISDI) Pediatric protocol was  a prospective
cohort  study that enrolled and followed HIV-infected children
at  multiple clinical sites in Latin America between 2002 and
2011.  The primary purpose of the study was  to describe the
demographic, clinical, immunological and virologic charac-
teristics  of HIV-infected children and youth at participating
clinical sites, as well as characterize outcomes related to
HIV  disease, including exposure to ARV treatment. A detailed
description of this study has been published elsewhere.13Brieﬂy, HIV-infected children and youth <21 years of age were
enrolled  at outpatient clinics and treated with ART accord-
ing  to each country’s standard protocol. Historical laboratory
and  clinical data were  systematically collected at enrollment; 0 1 5;1  9(1):23–29
protocol  evaluations, including medical and treatment his-
tory  and clinical and laboratory assessments, were  conducted
every  six months. The protocol was  approved by the eth-
ical  review boards at each clinical site, by the sponsoring
institution (NICHD), the data management and statistical cen-
ter (Westat), and the Brazilian National Ethics Committee
(CONEP). Informed consent was obtained from parents and/or
guardians.
This  case series was  obtained from a retrospective medical
record  review of all TB cases reported among HIV infected sub-
jects  participating in the NISDI Pediatric protocol (2002–2007)
and  prospective case ascertainment after 2007. Participating
clinical sites in Brazil (eleven sites), Argentina (two sites), Peru
(two  sites), and Mexico (two sites) were  asked to: (1) review
the  medical records for all subjects with a clinical diagno-
sis  of TB, or any diagnosis where Mycobacterium tuberculosis
was  cultured; and (2) complete a TB case report form for
each  case. Data collected from available medical records at
the  time of diagnosis included the basis for the TB diagno-
sis  (laboratory, epidemiological, radiological, clinical signs and
symptoms);  the clinical presentation of TB; receipt of ART
prior  to the TB diagnosis; receipt of anti-TB drug therapy; and
CD4  and viral load nearest (within six months before and one
month  after) the time of TB diagnosis. HAART was  deﬁned
as  at least three anti-retroviral medications from at least two
classes.
To  be included in this case series, each subject had to have
documentation of having been prescribed anti-TB therapy and
some  evidence of TB obtained from the medical records at the
time  of the TB diagnosis. Cases were  classiﬁed in one of three
ways:  laboratory-conﬁrmed, clinically conﬁrmed, or presumed
TB.
The  diagnosis of TB was  considered laboratory-conﬁrmed if
one  or more  of the following conditions were met:
•  Isolation of M. tuberculosis from a clinical specimen.
• Demonstration of M.  tuberculosis complex from a clinical
specimen by nucleic acid ampliﬁcation test.
• Demonstration of acid-fast bacilli in a clinical specimen
when a culture had not been or could not be obtained.
•  Histopathology consistent with TB.
In the absence of any laboratory evidence, TB was classiﬁed
as  clinically conﬁrmed if all of the following conditions were  met:
•  A positive tuberculin skin test (≥5 mm induration) for M.
tuberculosis.
•  Clinical signs and symptoms (e.g., fever, cough, weight
loss),  radiologic evidence (e.g., abnormal chest radiograph
[CXR], abnormal chest computerized tomography [CT] scan
or  ultrasound evidence of hepatomegaly, splenomegaly,
and/or lymphadenopathy) compatible with TB.
•  Treatment with two or more  anti-TB medications.
If a case could not be classiﬁed as laboratory- or clin-
ically conﬁrmed, the case was  considered presumed TB if
the  subject was  treated with three or more  anti-TB medica-
tions  and there was  evidence in at least two of three broad
categories (epidemiologic, radiologic, clinical signs or symp-
toms).
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Reported TB cases
N=103
Medical records
available at time of TB
diagnosis
n=79 (76.7%)
No medical records
N=24 (23.3%)
Treated TB
N=76 (96.2%)
Radiologic evidence: N=21 (95.5%)
Signs/symptoms: N=19 (86.3%)
Epidemiologic evidence: N=14 (63.65%)
Radiologic evidence: N=23 (63.9%)
Signs/symptoms: N=33 (91.7%)
Epidemiologic evidence: N=14 (38.9%)
Radiologic evidence: N=10 (90.9%)
Signs/symptoms: N=8 (72.7%)
Epidemiologic evidence: N=4 (36.4%)
TB confirmed
Laboratory*
N=36 (76.6%)
Clinical*
N=11 (23.4)
N=47 (68.1%)
Lack sufficient evidence
to classify as confirmed
or presumed
N=7 (9.2%)
M. aviwn (n=1),
no TB medication (n=2)
N=3 (3.8%)
TB presumed*
N=47 (68.1%)
* All subjects in the final case series had more than one type of evidence for TB.
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 Report of close contact with an active TB case was  consid-
ered  epidemiologic evidence.
 Radiological evidence included (1) CXR and/or CT demon-
strating cavitation, hilar lymphadenopathy, an inﬁltrate, or
ﬁndings consistent with miliary TB and/or (2) ultrasound
evidence of the following: hepatomegaly, splenomegaly
and/or lymphadenopathy.
 Clinical signs/symptoms included a report of symptoms
compatible with TB (cough, fever, weight loss, lym-
phadenopathy, or liver and/or spleen enlargement).
Those cases with insufﬁcient evidence for classiﬁcation as
utlined  above were  not included in the ﬁnal case series.
A  clinical response to treatment with anti-tuberculosis
edication was  deﬁned as a return to normal temperature
fter reported fever and/or gaining 10% of body weight among
hose  who had previously lost 10% of their body weight one
onth  prior to the diagnosis of TB.
esultsf the 1114 HIV-infected infants, children, and adolescents
nrolled in NISDI, 103 (9.2%) had some mention of TB in
heir  case report forms and 79 (76.7%) of these had medi-
al  records available at the time of the TB diagnosis (Fig. 1). classiﬁcation of reported TB cases.
Of  these 79 cases, one was excluded for a positive culture
for  Mycobacterium avium and two were  excluded as there was
no  documentation of treatment for TB. Of the remaining 76
subjects,  seven lacked sufﬁcient evidence for classiﬁcation
and were  excluded, resulting in 69 TB cases to be described,
of  which 36 (52.2%; 95% CI: 39.8–64.4) were classiﬁed as
laboratory-conﬁrmed TB, 11 (15.9%; 95% CI: 8.2–26.7) as clin-
ically  conﬁrmed TB, and 22 (31.9%; 95% CI: 21.2–44.2) as
presumed TB. Thus, 87.3% (69/79) of reported TB could be clas-
siﬁed  by our chart review.
As  shown in Table 1, among these 69 TB cases, 49 (71.0%)
were  from Brazil, reﬂecting the overall distribution of enroll-
ments  in the cohort; 66 (95.7%) had perinatally acquired HIV
infection,  and the majority (84.1%) had received BCG vaccina-
tion.  Of the 52 subjects with information available on contact
history,  32 (61.5%) had a history of contact with an adult TB
case,  with 94% of these reporting daily contact with this per-
son.  The median age at TB diagnosis was 2.5 years, ranging
from  birth to 22 years of age. No deaths from TB occurred
among these 69 cases during study follow-up.
Clinical  features/presentation  and  diagnostic  methodsSixty cases (87.0%) had symptoms consistent with TB recorded
with  the remaining nine (13%) subjects missing informa-
tion  regarding their symptoms (Table 1). Fever was  the most
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Table 1 – Demographic and clinical features of the 69
tuberculosis (TB) cases.
Variable n (%)
Country of origin
Argentina 3  (4.3)
Brazil 49 (71.0)
Mexico 7 (10.1)
Peru 10 (14.5)
Gender
Male 37 (53.6)
Female 32 (46.4)
Mode of HIV acquisition
Perinatal  66 (95.7)
Horizontal 3 (4.3)
History of contact with adult TB case
Yes 32 (61.5)
No 20 (38.5)
Missing 17
BCG vaccination
Yes 58  (84.1)
Not conﬁrmed 11 (15.9)
If yes, age at BCG vaccination (months)
<12  51 (94.4)
≥12 3 (5.6)
Missing 4
If yes, months since BCG at TB diagnosis
<12  16 (30.2)
12 < 24 8 (15.1)
≥24 29 (54.7)
Missing 5a
Age at TB diagnosis (years)
<1  20 (29.0)
1–4 27 (39.1)
5–14 19 (27.5)
>14 3 (4.4)
Median 2.5
Range Birth to 22
Relationship of TB diagnosis (dx) to ART
TB dx prior to any ART 25 (36.2)
TB dx within 3 days of starting any ART 3 (4.3)
TB dx after being on ART >3 days 39 (56.5)
Missing ART dates 2 (2.9)
Clinical presentation
Pulmonary 33 (47.8)
Miliary 24 (34.8)
Lymphadenitis 9 (13.0)
Other 3 (4.4)
Clinical features
Any  symptoms consistent with TB 60 (87.0)
Unknown/missing 9 (13.0)
Fever
Yes 42 (70.0)
No 18 (30.0)
Cough
Yes 39 (65.0)
No 21 (35.0)
Weight loss within 1 month
Yes 22 (36.7)
No 38 (63.3)
Table 1 (Continued)
Variable n (%)
Lymphadenopathy
Yes 7 (11.7)
No  53 (88.3)
Hospitalization for ≥28 days
Yes  42 (60.9)
No  or unknown 27 (39.1)a One case of TB occurred prior to BCG administration.
frequent symptom recorded (70%), with most fevers last-
ing  ≥14 days [24/42 (57.1%)], followed by cough (65%), recent
(within  1 month) weight loss (36.7%), and lymphadenopathy
(11.7%).
Pulmonary TB was  the most frequent diagnosis (47.8%), fol-
lowed  by miliary TB (34.8%), and TB lymphadenitis (13.0%)
(Table  1). Table 2 shows the clinical presentation of the TB
cases  and how they were diagnosed and distributed by age
category.
Among  the 36 laboratory-conﬁrmed cases, 18 (50.0%) had
a  positive culture and another 18 (50.0%) had at least one
specimen positive for acid fast bacilli (AFB) and/or histopath-
ology  suggestive of TB (one by histopathology alone) (data not
shown).
Among  61 records reporting CXR and/or CT exams, 54
(88.5%)  were  abnormal; 18 (33.3%) of the 54 were  read as
miliary  TB, 15 (27.8%) with local or diffuse inﬁltrates, 14
(25.9%)  with hilar/lymph node enlargement, three (5.6%) with
cavitation  and four (7.4%) other. Eleven (84.6%) of the 13
abdominal ultrasounds performed demonstrated hepatomeg-
aly,  splenomegaly, and/or lymphadenopathy.
Tuberculin skin tests were recorded for 37 (53.6%) of the
69  TB cases, of which 16 (43.2%) were positive. Five out of 16
(31.3%)  tests among the 36 bacteriologically conﬁrmed cases
were  positive.
Clinical  response  to  treatment
Among 61 cases with available weight and fever information,
72.5%  (n = 44) demonstrated a positive response after TB treat-
ment;  17 (27.5%) charts documented both an increase in body
weight  of ≥10% and disappearance of fever, and 27 (44.9%)
documented either an increase of ≥10% in body weight or
disappearance of fever (data not shown).
Timing  of  TB  and  ART
The vast majority (87.0%) of TB cases were diagnosed prior
to  enrollment into NISDI; only nine cases of TB (13.0%) were
diagnosed  after study enrollment. Most ART start dates also
occurred  prior to study enrollment. Two (2.9%) cases did not
have  ART start dates available, 25 (36.2%) cases of TB were
diagnosed prior to the start of ART, three (4.3%) had the diag-
nosis  of TB and ART initiation occur within three days of each
other,  and 39 (56.5%) cases were on ART [26 were on HAART-
PI,  three on HAART-NNRTI, and ten on dual therapy] prior to
TB diagnosis (Table 1). Eleven of the 39 cases on ART prior to
TB  diagnosis had been on HAART for less than three months
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Table 2 – Tuberculosis (TB) cases by age at time of TB diagnosis, clinical presentation, and type of evidence used for
diagnosis.
Age at time of TB diagnosis Clinical presentation Type of evidence used for diagnosis Total
Laboratory conﬁrmed TB Clinically conﬁrmed TB Presumed TB
0 ≤ 12 mo Lymphadenitis 2 1 0 3
Miliary TB 5 2 1 8
Pulmonary TB 6 1 1 8
Congenital TB 1 0 0 1
1–4 yr Lymphadenitis 3 0 0 3
Miliary TB 3 2 6 11
Pulmonary TB 4 2 7 13
5–14 yr Lymphadenitis 2 0 1 3
Miliary TB 2 0 2 4
Pulmonary TB 7 2 2 11
Renal TB (6 yr) 0 1 0 1
>14 yr Lymphadenitis 0 0 0 0
Miliary TB 0 0 1 1
Pulmonary TB 0 0 1 1
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Total 36  
hen TB manifested itself and another ﬁve cases were  diag-
osed  between three and six months following initiation of
IV  treatment (data not shown).
mmunological  markers
n the majority of cases no CD4 counts were  available at the
ime  of TB diagnosis. Twenty eight cases had CD4 results avail-
ble  within six months before or one month after TB diagnosis:
1  (39.3%) had CD4% <15%, 12 (42.9%) had CD4% between
5%  and 25%, and ﬁve (17.9%) had CD4% >25%. There was no
pparent  association between CD4 percentages and clinical
resentation (data not shown).
iscussion
f the 1114 HIV-infected subjects enrolled in the NISDI study,
03  (9.2%) had some mention of TB in their case report forms.
his  crude prevalence is similar to the 7.4% (51/689) prevalence
eported among Kenyan children enrolled in a prospective
tudy from six weeks to 14 years of age.14
Of the 79 available medical records, 69 (87.3%) contained
ufﬁcient evidence to classify these cases as follows: 52.2%
95%  CI: 39.8–64.4) were  classiﬁed as laboratory-conﬁrmed TB,
5.9% (95% CI: 8.2–26.7) as clinically conﬁrmed TB, and 31.9%
95%  CI: 21.2–44.2) as presumed TB. As previously noted, the
iagnosis  of TB in children is a challenging task, often requir-
ng  reliance on clinical, epidemiological, and radiographic
riteria.
Among 218 children with symptoms suggestive of pul-
onary  tuberculosis (cases) that enrolled from August, 2002,
o  January, 2007 at two hospitals in Lima, Peru, only 22 (10%)
ad  at least one positive M. tuberculosis culture.15 In contrast,
n  our case series, 26% (18/69) of cases were culture conﬁrmed,
erhaps due, in part, to the strict criteria utilized to classify
ases.
Thirty-nine (56.5%) subjects were  receiving ART at least
hree  or more  days prior to TB diagnosis, with eleven cases0 0 1
11 22 69
receiving  ART for less than three months when TB was diag-
nosed  and ﬁve cases diagnosed between three and six months
following  initiation of ART. Given the timing ART initiation
in  relationship to the timing of TB diagnosis, these 16 (23%)
cases  may  represent immune reconstitution inﬂammatory
syndrome (IRIS). A recent systematic literature review of TB
IRIS  found only thirteen pertinent studies.16 They found the
median  time from start of ART to TB IRIS diagnosis (reported by
eight studies) ranged from eight days to 16 weeks. This review
included  only one study from Latin America, that reported on
two cases of disseminated BCG in HIV infected children less
than  one year of age.17 Thus, our report of 16 potential TB IRIS
cases  from Latin America is the largest we  are aware of.
There  are some potential limitations of this study that are
worth  noting when interpreting the results. In Latin Ameri-
can  countries, BCG immunization is recommended in the ﬁrst
month  of life because of its proven efﬁcacy in avoiding severe
forms  of the disease.18 It is however not recommended in chil-
dren  with symptomatic HIV disease because of its potential
to  cause severe local or even disseminated disease.19,20 Most,
if  not all, children in this cohort were not known to be HIV-
infected  at the time they received BCG, so it is not possible to
exclude  the Mycobacterium bovis strain as the cause of one or
more  cases in the present cohort.
In this observational cohort, most cases of TB (87%)
occurred prior to enrollment into NISDI, and therefore, were
based  on chart review which may  have missed important clin-
ical  and epidemiological details. Patients were  enrolled at 15
sites  in four countries over nine years, thus standard of care for
diagnosis and treatment of TB and HIV could have varied con-
siderably  over time and across sites. Despite these limitations
we  could classify the majority of cases reported.
A recent report by WHO21 shows that this region of the
Americas is second to Africa with respect to prevalence of HIV
among  TB patients; 44% of TB patients in Africa found to be
HIV-positive compared to 17% in the region of the Americas.
In  fact, the diagnosis of TB may  have led to the HIV diagnosis
in  our study, since over one-third of the TB cases were  not on
ART  until months to years later. Therefore, there is an urgent
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need to ﬁnd, prevent and treat TB in people living with HIV,
and  to screen for HIV and TB in children upon diagnosis of
either  condition.
Our  ﬁnding that nearly half of all cases (32) had a history
of  contact with an adult TB case emphases the need for more
aggressive  contact tracing among adult TB cases and provision
of  preventive therapy for exposed HIV infected children.
Research on optimizing preventive strategies in TB-
exposed, HIV-infected children is needed.
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